title: Pluristem Therapeutics, Inc.
abstract: Pluristem Therapeutics, Inc., based in Haifa, Israel, is a regenerative, biotherapeutics Company dedicated to the commercialization of nonpersonalized (allogeneic) cell therapy products. The Company is expanding noncontroversial placental-derived mesenchymal stem cells via a proprietary 3D process, named PluriX, into therapeutics for a variety of degenerative, malignant and autoimmune disorders. Pluristem will be conducting Phase I trials in the USA with its first product, PLX-I, which addresses the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of hematopoietic stem cells contained in umbilical cord blood.
authors.affiliation: Pluristem Therapeutics, Inc, MATAM Advanced Technology Park #20, Haifa 3190, Israel. bill@pluristem.com
authors.forename: William
authors.initials: W
authors.lastname: Prather
mesh_terms: D001709:Biotechnology; D017690:Cell Transplantation; D006801:Humans; D007221:Industry; D007557:Israel; D059630:Mesenchymal Stem Cells / Q000166:cytology